CINECA IRIS Institutional Research Information System

MOLINARO, ELEONORA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.444
EU - Europa 4.324
AS - Asia 3.107
SA - Sud America 513
AF - Africa 206
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 14.599
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.283
DE - Germania 1.602
SG - Singapore 1.014
CN - Cina 913
IT - Italia 733
SE - Svezia 640
HK - Hong Kong 512
BR - Brasile 435
GB - Regno Unito 403
BG - Bulgaria 219
AT - Austria 200
VN - Vietnam 139
RU - Federazione Russa 138
TR - Turchia 133
CA - Canada 120
FI - Finlandia 94
CI - Costa d'Avorio 91
IN - India 91
FR - Francia 73
SN - Senegal 66
UA - Ucraina 63
KR - Corea 62
JP - Giappone 60
BD - Bangladesh 31
AR - Argentina 27
NL - Olanda 25
PL - Polonia 25
MX - Messico 22
BE - Belgio 20
MA - Marocco 19
IQ - Iraq 18
CH - Svizzera 17
UZ - Uzbekistan 16
ES - Italia 15
VE - Venezuela 15
ZA - Sudafrica 15
PK - Pakistan 13
CO - Colombia 12
EC - Ecuador 12
ID - Indonesia 10
IR - Iran 10
PH - Filippine 9
SA - Arabia Saudita 9
AE - Emirati Arabi Uniti 8
GR - Grecia 8
LT - Lituania 8
AZ - Azerbaigian 7
MY - Malesia 7
CZ - Repubblica Ceca 6
IL - Israele 6
JM - Giamaica 6
NP - Nepal 6
CY - Cipro 5
EE - Estonia 5
IE - Irlanda 5
SK - Slovacchia (Repubblica Slovacca) 5
TN - Tunisia 5
HU - Ungheria 4
JO - Giordania 4
RS - Serbia 4
UY - Uruguay 4
AU - Australia 3
BH - Bahrain 3
EG - Egitto 3
KG - Kirghizistan 3
LB - Libano 3
PT - Portogallo 3
BY - Bielorussia 2
BZ - Belize 2
CL - Cile 2
DZ - Algeria 2
HN - Honduras 2
KE - Kenya 2
KZ - Kazakistan 2
LK - Sri Lanka 2
MK - Macedonia 2
OM - Oman 2
PE - Perù 2
PY - Paraguay 2
SV - El Salvador 2
AL - Albania 1
BJ - Benin 1
BO - Bolivia 1
DK - Danimarca 1
DM - Dominica 1
DO - Repubblica Dominicana 1
GA - Gabon 1
GE - Georgia 1
GT - Guatemala 1
HR - Croazia 1
KH - Cambogia 1
KI - Kiribati 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
MN - Mongolia 1
NG - Nigeria 1
NI - Nicaragua 1
NO - Norvegia 1
PA - Panama 1
Totale 14.591
Salva come PNG Salva come JPEG
Città #
Ashburn 792
Dallas 678
Singapore 534
Woodbridge 514
Hong Kong 508
Fairfield 436
Chandler 413
Santa Clara 405
Ann Arbor 311
Houston 276
Sofia 219
Shanghai 215
Milan 210
Seattle 205
New York 203
Beijing 195
Vienna 185
Cambridge 172
Wilmington 159
Los Angeles 128
London 109
Princeton 104
Boardman 103
Munich 96
Abidjan 91
Lawrence 83
Ottawa 82
Hefei 68
Jacksonville 68
Dakar 66
Florence 64
Pisa 64
Frankfurt am Main 62
Medford 61
Izmir 59
Seoul 56
Serra 47
Tokyo 47
Istanbul 46
Bremen 44
Dearborn 43
Rome 41
Des Moines 40
Nanjing 40
Redondo Beach 38
Dong Ket 36
São Paulo 34
San Diego 32
Buffalo 28
Boulder 23
Turku 23
Düsseldorf 22
Hanoi 22
Helsinki 21
Ogden 21
Ho Chi Minh City 20
Redwood City 20
Brussels 19
Redmond 19
Lancaster 18
Nanchang 18
Chicago 17
Nürnberg 17
Columbus 16
Fuzhou 16
Changsha 15
Denver 15
Guangzhou 15
Pune 14
Quanzhou 14
Rio de Janeiro 14
San Francisco 14
Tashkent 14
Bern 13
Montreal 13
Orem 13
Warsaw 13
Belo Horizonte 12
Chennai 12
Norwalk 12
Stockholm 12
Zhengzhou 12
Casablanca 11
Jüchen 11
Kunming 11
Toronto 11
Washington 11
Atlanta 10
Brooklyn 10
Jiaxing 10
Baghdad 9
Chengdu 9
Council Bluffs 9
Nuremberg 9
Philadelphia 9
Poplar 9
Tianjin 9
Boston 8
Brasília 8
Falkenstein 8
Totale 9.221
Salva come PNG Salva come JPEG
Nome #
Surgical treatment of low- and intermediate-risk papillary thyroid cancer with minimally invasive video-assisted thyroidectomy 308
Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line. 270
ALL-TRANS RETINOIC ACID TREATMENT INHIBITS THE GROWTH OF RARb mRNA EXPRESSING THYROID CANCER CELL LINES BUT DOES NOT RE-INDUCE THE EXPRESSION OF THYROID SPECIFIC GENES 242
Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. 241
Low-Risk Differentiated Thyroid Cancer with BRAFV600E mutation is more difficult to cure than negative cases: a 5-year follow-up study. 236
Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies 235
Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line 230
Treatment of advanced thyroid cancer with targeted therapies: Ten years of experience 224
Changing Trend of Thyroglobulin Antibodies in Patients with Differentiated Thyroid Cancer Treated with Total Thyroidectomy Without ¹³¹I Ablation 221
The presence of a tall cells>10% in a classical variant of papillary thyroid carcinoma (CV-PTC) makes its aggressiveness similar to that of tall cell variant (TCV-PTC) 221
Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients 219
Targeted Therapy in Thyroid Cancer: State of the Art 210
Ret Genetic Screening in Patients with Medullary Thyroid Cancer and Their Relatives: Experience with 807 Individuals at One Center 209
Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at one single Italian center 206
All-trans Retinoic Acid treatment inhibits the growth of RARb mRNA expressing thyroid cancer cell lines but does not re-induce the expression of thyroid specific genes 203
CLINICAL IMPACT OF RET GENETIC SCREENING IN THE MANAGEMENT OF MEDULLARY THYROID CARCINOMA (MTC) PATIENTS: 20 YEARS OF EXPERIENCE 200
Use of low-dose radioiodine ablation for Graves' orbitopathy: results of a pilot, perspective study in a small series of patients 199
RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC) 198
RET point mutations in Thyroid Carcinoma 196
Management of thyrotoxicosis induced by PD1 or PD-L1 blockade 194
Nuove indicazioni all’impiego del TSH umano ricombinante (rhTSH) e basse attività di 131I nella radioablazione del residuo tiroideo post-chirurgico. 188
Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal 185
Lung recurrence of papillary thyroid cancer diagnosed with antithyroglobulin antibodies after 10 years from initial treatment. 184
DIAGNOSTIC AND THERAPEUTIC ROLE OF THYROID REMNANT ABLATION WITH LOW ACTIVITY OF 131I IN PATIENTS WITH LOW AND INTERMEDIATE RISK PAPILLARY THYROID CARCINOMA (PTC). 183
Prevalence of papillary thyroid cancer (PTC) in patients affected by medullary thyroid cancer (MTC) 178
Thyroid autoantibodies and thyroid function in subjects exposed to Chernobyl fallout during childhood: evidence for a transient radiation-induced elevation of serum thyroid antibodies without an increase in thyroid autoimmune disease. 177
ROLE OF THYROID REMNANT ABLATION WITH LOW ACTIVITY OF 131I IN PATIENTS WITH LOW AND INTERMEDIATE RISK PAPILLARY THYROID CARCINOMA (PTC). 173
Il carcinoma tiroideo: nuove prospettive terapeutiche. 172
Successo terapeutico di Lenvatinib in seconda linea in un caso di carcinoma follicolare della tiroide avanzato 172
mRECIST criteria to assess recurrent thyroid carcinoma treatment response after radiofrequency ablation: a prospective study 169
The Molecular Signature More Than the Site of Localization Defines the Origin of the Malignancy 168
Vandetanib and the predictive factors of durable response in locally advanced or metastatic medullary thyroid cancer: a single center experience. 168
BRAFV600E mutation is an indipendent predictive prognostic factor for persistent/recurrent disease in low risk differentiated Thyroid cancer patients: a 5 year follow-up study. 167
Early treatment of hereditary medullary thyroid carcinoma after attribution of multiple endocrine neoplasia type 2 gene carrier status by screening for ret gene mutations 166
Potential impact of BMI on the aggressiveness of presentation and clinical outcome of Differentiated Thyroid Cancer 164
Fifty years after the first description, the MEN 2B syndrome diagnosisis still late: description of two recent cases 162
The stage of differentiated thyroid cancer at diagnosis is significantly more advanced in children than in adolescent 161
Thyroid consequences of the Chernobyl nuclear accident. 160
Recombinant human TSH (rhTSH) in 2009: new perspectives in diagnosis and therapy 159
Thyroglobulin changes are highly dependent on TSH in low-risk DTC patients not treated with 131I 159
In vitro studies of retnoic acid treatment of human anaplastic, poorly differentiated papillary, follicular and medullary thyroid cancer cell lines 158
Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma 152
A rare adverse event (AE) in a group of radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) patients in therapy with lenvatinib. 152
Lenvatinib treatment in the real clinical practice of progressive, radioiodine-refractory differentiated thyroid carcinoma: analysis of a big series followed in a single center 152
Outcome of classical (CVPTC) and follicular (FVPTC) variants of papillary thyroid cancer: 15 years of follow-up 151
Osteonecrosis of the jaw: a rare but possible side effect in thyroid cancer patients treated with tyrosine-kinase inhibitors and bisphosphonates 151
Advantages and disadvantages of prophylactic central compartment lymph node dissection for differentiated thyroid cancer: the first randomized controlled study from a single referral center. 150
Clinically unpredictable prognostic factors in the outcome of medullary thyroid cancer 147
null 146
Tall cell percentage alone in PTC without aggressive features should not guide patients’ clinical management 146
Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. 145
No difference in the outcome of metastatic thyroid cancer patients when using recombinant or endogenous TSH 145
Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma 143
Failure to use measurement of megalin secretory components complexed with serum thyroglobulin as a tool to identify metastases after surgery in papillary thyroid cancer. 143
Low specificity of blood thyroglobulin messenger ribonucleic acid assay prevents its use in the follow up of differentiated thyroid cancer patients 141
Ca19.9 positivity and doubling time are prognostic factors of mortality in patients with advanced medullary thyroid cancer with no evidence of structural disease progression according to RECIST 141
OR21-01 Pre-Operative Calcitonin Value as a Predictive Factor of Cancer Related Death in Sporadic Medullary Thyroid Carcinoma 141
Studi in vitro del trattamento con acido retinico di linee di carcinoma tiroideo umano anaplastico, poco differenziato, follicolare e midollare 138
Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. 137
Clinical impact of molecular techniques for the presurgical diagnosis of differentiated thyroid cancer diagnosis 134
Impact of Advanced Age on the Clinical Presentation and Outcome of Sporadic Medullary Thyroid Carcinoma 132
Carcinoma tiroideo e gravidanza. 131
Delayed radioiodine remnant ablation (RRA) does not impact on the outcome of intermediate risk for recurrence differentiated thyroid cancer patients (IR-DTC). 128
Radioiodine remnant ablation (RRA) Impact on the dynamic risk of restratification in the short-term follow-up of patients with differentiated thyroid cancer (DTC). 119
Assessing mPTC Progression during Active Surveillance: Volume or Diameter Increase? 119
Use of low-dose radioiodine ablation for Graves’ orbitopathy: results of a pilot, perspective study in a small series of patients 118
Yttrium-90 transarterial radioembolization for liver metastases from medullary thyroid cancer 116
The outcome of metastatic differentiated thyroid cancer is similar in patients prepared for 131-I therapy with recombinant TSH or Hypothyroidism. 115
null 114
Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid Cancer 114
Significance of Thyroglobulin Autoantibodies in Patients With Thyroid Cancer Treated With Lenvatinib 113
Impact of the Stimulation method Used for 131-Therapy in Patients With Differentiated Thyroid Cancer. 113
Significato prognostico della mutazione di BRAF in pazienti affetti da carcinoma papillare della tiroide con follow-up di 20 anni. 110
A novel fusion RET/PTC3 involving NCOA4 and RET genes in a pediatric case of Papillary Thyroid Carcinoma 108
null 107
Ablazione del residuo tiroideo post chirurgico con rhTSH e 30 mCi. 106
null 105
Papillary thyroid microcarcinoma: Toward an active surveillance strategy 105
Active surveillance in differentiated thyroid cancer: a strategy applicable to all treatment categories response 103
null 103
Non thyroidal second primary malignancies in differentiated thyroid cancer patients: is the incidence increased comparing to the general population and could it be a radioiodine therapy consequence? 102
Follicular (FVPTC) VS Classical (CVPTC) variant of papillary thyroid cancer: correlation of the outcome after 12 years of follow up. 102
The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study 100
Single thyroid nodule 93
Molecular profiling of low-risk papillary thyroid carcinoma (mPTC) on active surveillance 92
Management of patients with extensive locally advanced thyroid cancer: results of multimodal treatments 91
The timing of total thyroidectomy in RET gene mutation carriers could be personalized and safely planned on the basis of serum calcitonin: 18 Years experience at one single center 90
Correction to: Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer (Journal of Endocrinological Investigation, (2021), 44, 10, (2139-2151), 10.1007/s40618-020-01491-3) 89
null 84
Management of patients with extensive locally advanced thyroid cancer: results of multimodal treatments 83
Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up. 80
Il carcinoma della tiroide 78
Adrenal insufficiency in thyroid cancer patients treated with tyrosine kinase inhibitors and detected by ACTH stimulation test 76
Tako-tsubo Syndrome as First Manifestation in a Case of Pheochromocytoma Developed From a Non-functional Adrenal Incidentaloma 75
Hand-foot syndrome in sorafenib and lenvatinib treatment for advanced thyroid cancer 72
Predictive factors for central neck compartment lymphnodes metastases' in sporadic medullary thyroid cancer patients 72
null 70
Ret Oncogene and Thyroid Carcinoma 68
How to manage patients with differentiated thyroid cancer and a rising serum thyroglobulin level. 62
Detection of metastases from differentiated thyroid cancer by different imaging techniques (neck ultrasound, computed tomography and [18F]-FDG positron emission tomography) in patients with negative post-therapeutic 131I whole-body scan and detectable serum thyroglobulin levels. 56
Totale 14.704
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.333
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.333
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021368 0 0 0 0 0 64 48 39 49 49 28 91
2021/20221.038 33 35 12 81 221 130 39 41 56 55 63 272
2022/20231.738 214 290 159 147 155 184 33 118 314 9 104 11
2023/20241.067 110 106 132 63 131 205 86 49 12 19 50 104
2024/20253.370 39 126 37 204 366 312 230 178 362 431 340 745
2025/20262.541 317 612 498 414 416 284 0 0 0 0 0 0
Totale 14.764